Foundational characteristics of cancer include proliferation, angiogenesis, migration, evasion of apoptosis, and cellular immortality. Find key markers for these cellular processes and antibodies to detect them.
The SUMOplot™ Analysis Program predicts and scores sumoylation sites in your protein. SUMOylation is a post-translational modification involved in various cellular processes, such as nuclear-cytosolic transport, transcriptional regulation, apoptosis, protein stability, response to stress, and progression through the cell cycle.
The Autophagy Receptor Motif Plotter predicts and scores autophagy receptor binding sites in your protein. Identifying proteins connected to this pathway is critical to understanding the role of autophagy in physiological as well as pathological processes such as development, differentiation, neurodegenerative diseases, stress, infection, and cancer.
Phospho-cJun(S63) Antibody
Affinity Purified Rabbit Polyclonal Antibody (Pab)
- SPECIFICATION
- CITATIONS: 1
- PROTOCOLS
- BACKGROUND
Application 
| IHC-P, DB, WB, E |
|---|---|
| Primary Accession | P05412 |
| Reactivity | Human |
| Host | Rabbit |
| Clonality | Polyclonal |
| Isotype | Rabbit IgG |
| Calculated MW | 35676 Da |
| Gene ID | 3725 |
|---|---|
| Other Names | Transcription factor AP-1, Activator protein 1, AP1, Proto-oncogene c-Jun, V-jun avian sarcoma virus 17 oncogene homolog, p39, JUN |
| Target/Specificity | This cJun Antibody is generated from rabbits immunized with a KLH conjugated synthetic phosphopeptide corresponding to amino acid residues surrounding S63 of human cJun. |
| Dilution | WB~~1:1000 IHC-P~~1:50~100 DB~~1:500 |
| Format | Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein A column, followed by peptide affinity purification. |
| Storage | Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles. |
| Precautions | Phospho-cJun(S63) Antibody is for research use only and not for use in diagnostic or therapeutic procedures. |
| Name | JUN |
|---|---|
| Function | Transcription factor that recognizes and binds to the AP-1 consensus motif 5'-TGA[GC]TCA-3' (PubMed:10995748, PubMed:22083952). Heterodimerizes with proteins of the FOS family to form an AP-1 transcription complex, thereby enhancing its DNA binding activity to the AP-1 consensus sequence 5'-TGA[GC]TCA-3' and enhancing its transcriptional activity (By similarity). Together with FOSB, plays a role in activation-induced cell death of T cells by binding to the AP-1 promoter site of FASLG/CD95L, and inducing its transcription in response to activation of the TCR/CD3 signaling pathway (PubMed:12618758). Promotes activity of NR5A1 when phosphorylated by HIPK3 leading to increased steroidogenic gene expression upon cAMP signaling pathway stimulation (PubMed:17210646). Involved in activated KRAS-mediated transcriptional activation of USP28 in colorectal cancer (CRC) cells (PubMed:24623306). Binds to the USP28 promoter in colorectal cancer (CRC) cells (PubMed:24623306). |
| Cellular Location | Nucleus. |
| Tissue Location | Expressed in the developing and adult prostate and prostate cancer cells. |
- Primary Antibodies
- Cancer
- Immunology
- Signal Transduction
- Antibody Collections
- Phospho Antibodies
- Anti-Wnt-Pathway (plus Lgr5) Antibodies
- Toll receptor signaling
- Toll-Like Receptor
- Toll-Like receptor signaling
- B cell receptor signaling
- T cell activation
- T cell receptor signaling
- Inflammation mediated by chemokine and cytokine signaling
- Apoptosis signaling
- SARS-Human interaction partners
Provided below are standard protocols that you may find useful for product applications.
Background
The gene for cJun is the putative transforming gene of avian sarcoma virus 17. The cJun protein is a transcription factor highly similar to the viral protein, and interacts directly with specific target DNA sequences to regulate gene expression. The gene maps to 1p32-p31, a chromosomal region involved in both translocations and deletions in human malignancies.
References
Cheng, J., et al., J. Biol. Chem. 280(15):14492-14498 (2005).
Quan, T., et al., J. Biol. Chem. 280(9):8079-8085 (2005).
Bladh, L.G., et al., Mol. Pharmacol. 67(3):815-826 (2005).
DeNardo, D.G., et al., Mol. Endocrinol. 19(2):362-378 (2005).
Cheung, E., et al., Proc. Natl. Acad. Sci. U.S.A. 102(3):559-564 (2005).
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.
Ordering Information
Other Products
Shipping Information
